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Introduction
health care has two ultimate goals, which are to prolong the 
life and to increase the quality of life. Measuring the health 
related quality of life gives important information about 
the health care progress. the chronic kidney disease affects 
more and more people in recent years and the need for 
transplantation increases (6). Worldwide there are 1.1 million 
patients registered in end-stage chronic kidney disease and 
their number increases with 7% per year. the prevalence of 
the disease is 135 per million inhabitants in europe and 336 
in the USA and increases permanently mainly as a result of 
diabetes progress. the survival after kidney transplantation 
is from 88% to 95% in the case when a dead or living donor 
is used, respectively (1). there are studies showing that the 
quality of life of patents with chronic kidney disease is severely 
hampered, but what happens after the kidney transplantation is 
relatively rarely studied (9).
the goal of our study was to analyze the cost of 
pharmacotherapy and quality of life of patents after kidney 
transplantation compared to those of patients with chronic 
kidney disease in Bulgaria.
Materials and Methods
A retrospective pharmacotherapy cost study and prospective 
health related quality of life study was performed during 2010 – 
2011 at the biggest Sofia hospital serving all transplant patients. 
the cost of pharmacotherapy was analyzed after reviewing 
records of all patients with chronic kidney disease and kidney 
transplantation. Mean cost per month was calculated for both 
diagnoses. 
the health related quality of life (qol) was evaluated with 
the multidimensional questionnaire SF-36. the SF-36 is a self 
administered questionnaire containing 36 items. it measures 
health on eight multi-item dimensions covering physical 
functioning, role limitations, bodily pain, social functioning, 
general mental health, role limitations due to emotional 
problems, vitality, energy or fatigue, general health perceptions. 
there is also health state self evaluation in comparison with 
the previous year. For each dimension, item scores are coded, 
summed, and transformed on to a scale from 0 (worst health) 
to 100 (best health) (7). the SF-36 was previously used and 
validated for Bulgaria for patients with chronic kidney disease 
(9). Sixty-two transplant and 19 patients with chronic kidney 
diseases were interviewed. 
Descriptive statistics, one way AnoVA analysis, Spearman 
correlation, and Kruskal-Wallis analysis were performed to 
evaluate the statistical significance of the differences in the QoL 
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The aim of the present study was to analyze the pharmacotherapy cost and quality of life of patents after kidney transplantation 
compared to those with chronic kidney disease in Bulgaria. This retrospective pharmacotherapy cost study and prospective 
health related quality of life (QoL) study was performed during 2010 – 2011 at the biggest Sofia hospital serving all transplant 
patients. The cost of pharmacotherapy was analyzed after reviewing patients’ records. The health related quality of life was 
evaluated with the multi-attributable questionnaire SF-36, which measures 9 health domains.
Forty-two percent of the patients with chronic kidney disease, and 26% of those with kidney transplant were female. The average 
age of the transplanted patients was 39.7 for male patients and 42.2 for female ones, while in the group suffering from chronic 
kidney disease the average male age was 48.3 and that of female patients, 51.2. No statistically significant difference was 
observed among the mean monthly cost of therapy per patient during the two-year period. The QoL was with lower values in 
the role limitations domain for patients with chronic kidney diseases and this difference was statistically significant. We found 
a correlation among the mean cost of pharmacotherapy and mean QoL in both groups of patients. In the group of patients with 
kidney transplantation the place of living and general health state were positively correlated. The cost of pharmacotherapy and 
the health state in comparison with the previous year were also positively correlated.
This is the first Bulgarian study of the quality of life of kidney transplant patients. It shows that the SF-36 could be successfully 
used in this group of patients as well as for comparison with the QoL of patients with chronic kidney disease. 
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in different groups of patients with different characteristics, as 
well as the correlation among the patients’ characteristics and 
qol. For Kruskal-Wallis test the gender and age data were 
dichotomized.
results and discussion
pharmacotherapy cost 
All the studied patients with chronic kidney disease were on 
hemodialysis and their pharmacotherapy included antianemic 
and blood formulating medicines. After the transplantation the 
therapy comprises mostly of immunosuppressors (Table 1).
TaBle 1 
Relative share of the prescribed medicines by inn* 
condition year 2010 year 2011 
chronic 
kidney 
disease
erythropoietin 94% erythropoietin 86.70%
calcitriol 68.80% calcitriol 40%
iron sucrose 93.80% iron sucrose 87.50%
Kidney 
transplant
azathioprine 21% azathioprine 18,1%
mycophenolic 
acid 80.00%
mycophenolic 
acid 76.60%
everolimus 1.60% everolimus 1.60%
mycophenolate 
mofetil 77.40%
mycophenolate 
mofetil 83.60%
tacrolimus 22.60% tacrolimus 24.60%
sirolimus 19.40% sirolimus 16.40%
ciclosporin 59.70% ciclosporin 57.40%
* inn: international nonproprietary names
No statistically significant difference was observed between 
the mean monthly cost of therapy per patient during the two 
years observed (Table 2).
TaBle 2
Mean monthly therapy cost (BGn)
condition
Mean 
monthly 
therapy cost 
2010
Mean 
monthly 
therapy cost 
2011
one way  
anoVa 
analysis
(p)
Kidney 
transplant 528.5557 445.3723 0.249136
chronic 
kidney disease 431.3271 420.8616 0.9626
quality of life
All observed patients were inquired with SF-36. Forty-two 
percent of the patients with chronic kidney disease and 26% 
of those with kidney transplant were female. the average age 
of the male transplanted patients was 39.7 and for the female 
ones, 42.2; while in the group with chronic kidney disease the 
average male age was 48.3 and that of the female patients, 51.2.
the qol measured with the SF-36 was with lower values 
in the role limitations domain for patients with chronic kidney 
diseases (fig. 1). This difference was statistically significant 
in comparison with transplant patients (AnoVA, P < 0.05) – 
Table 3 and Table 4. it might be supposed that the necessity 
of frequent hemodialysis significantly limits the everyday life. 
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fig. 1. Average value of SF-36 domains in the two groups.
TaBle 3
Descriptive statistics – kidney transplantation
 Minimum Maximum Mean standard deviation
PhysFunc .00 100.00 69.1354 31.71121
Rolelim .00 100.00 55.0000 39.82383
Pain .00 100.00 75.4308 26.58843
SocAct 25.00 100.00 72.2308 20.90306
Psychhealth 12.00 100.00 65.2938 18.83082
emotProb .00 100.00 63.0785 43.75135
VitenFat 20.00 75.00 52.0154 12.03315
Generhealt 5.00 100.00 49.8523 18.72696
healthPrYear 25.00 100.00 56.5385 17.82999
TaBle 4
Descriptive statistics – chronic kidney disease
 Minimum Maximum Mean standard deviation
PhysFunc .00 100.00 56.9967 28.03885
Rolelim .00 100.00 23.3333 38.34368
Pain 32.50 100.00 70.6667 24.06217
SocAct 25.00 100.00 65.8333 23.36944
Psychhealth 24.00 92.00 57.8667 18.81438
emotProb .00 100.00 44.4333 43.03623
VitenFat 35.00 65.00 49.3333 7.76132
Generhealt 20.00 70.00 39.0000 14.41725
healthPrYear .00 75.00 48.3333 19.97022
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in both diagnoses the mean quality of life is lower than the 
maximum possible 100 points in all domains (fig. 1). Patients 
with chronic kidney diseases are with lower qol in all domains 
in comparison with transplanted patients. the differences in 
the quality of life are statistically significant (ANOVA, P = 
0.0076). the higher mean values of the qol in patients with 
kidney transplantation are probably due to the fact that the 
successful transplantations ensure normal life. 
We found a correlation between the mean cost of 
pharmacotherapy and the mean qol in the patients with 
kidney transplantation but not in the group with chronic 
kidney disease. the correlation is positive which means that 
the increase in the cost of pharmacotherapy should lead to 
increased qol of patients (Table 5). the lack of correlation in 
the second group of patients could be commented with the final 
stage of the chronic kidney disease where little could be done 
to improve the quality of life.  
TaBle 5
correlation between the mean qol and cost of pharmacotherapy
condition Mean qol
Mean 
monthly cost 
of therapy in 
2011 (Bgn)
spearman 
correlation 
coefficient
Kidney 
transplant 61.9784 445.37 0.298
chronic 
kidney disease 47.4788 420.86 no
TaBle 6
correlations within the groups of patients with kidney 
transplantation
correlated variables spearman correlation 
coefficient
General health and place of living 0.328 (0.01 cl)
cost of pharmacotherapy and 
health state in comparison with the 
previous year
0.258 (0.01 cl)
0.302 (0.01 cl)
TaBle 7
correlations within the group of patients with chronic kidney 
diseases 
correlated variables spearman correlation 
coefficient
cost of pharmacotherapy and 
pain 0.532 to 0.632 (0.05 cl)
cost of pharmacotherapy and 
general health state 0.515 (0.05 cl)
the correlation between the characteristics of patients and 
particular domains of the qol were further evaluated with 
Spearman test (Table 6 and Table 7). in the group of patients 
with kidney transplantation the place of living and general 
health state were correlated positively and people living in the 
towns were shown to have better quality of life, probably due 
to the fact that they are closer to the health care services (Table 
6). the cost of pharmacotherapy and health state in comparison 
with the previous year was also positively correlated, so with 
the increase of the cost the health care state self-evaluation 
improves.
in patients with chronic kidney disease the cost of 
pharmacotherapy and general health state were positively 
associated and the increase in the cost of therapy was found to 
benefit the patients’ general health state evaluation, as well as 
to diminish the pain (Table 7).
the kidney transplantation is the only cure for chronic 
kidney disease. it aims to increase the patients’ life expectancy 
through optimal kidney functioning. A variety of factors 
could influence the success of the transplantation and among 
them are the compatibility among the donor and recipient, 
immunological status, age, availability of infections, surgical 
complications, quality of life before the transplantation etc. (8). 
in this sense the studies of the quality of life of transplanted 
patients are important for the evaluation of the success of 
transplantation and its impact on the daily life (7). 
After its development in 1980 the SF-36 became one of 
the most often used multidimensional instruments for qol 
measurement (3, 5). the use of SF-36 in our study was also 
based on the previous experience gained with the patients with 
chronic kidney disease in Bulgaria (9). Our study confirmed 
the results of the previous one that the chronic kidney disease 
severely hampers the quality of life. It also confirmed the results 
of other studies that the psychological well-being is affected 
worst (2). Some new evidence is added for the significant 
influence of the transplantation on the QoL. In addition the 
study reveals that the access to health care and higher spending 
on pharmaceuticals also influences positively the QoL of 
transplant patients. the cost of therapy as an important qol 
determinant was also confirmed (4). 
our study has some limitation as is the fact that it is not a 
long-term analysis but just a shot of the current state of the art. 
Further inquiries should be done to evaluate the long-term qol 
after the transplantation.
conclusions
This is the first Bulgarian study of the quality of life of kidney 
transplant patients. it shows that the SF-36 could be successfully 
used in this group of patients as well as for comparison with 
the qol of patients with chronic kidney disease. 
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